本文選題：繼發(fā)性甲狀旁腺功能亢進　切入點：血液透析　出處：《安徽醫(yī)科大學學報》2017年07期 　論文類型：期刊論文

【摘要】：探討骨化三醇不同給藥方式治療維持性血液透析患者繼發(fā)甲狀旁腺功能亢進的療效。選擇醫(yī)院血液凈化中心血液透析合并繼發(fā)性甲旁亢患者40例,分為靜脈骨化三醇聯(lián)合血液透析濾過組(治療組)和口服骨化三醇聯(lián)合血液透析濾過組(對照組)。依據(jù)全段甲狀旁腺激素(iPTH)水平每組再分為2個亞組,治療組1和對照組1(300 pg/ml≤iPTH≤600 pg/ml)、治療組2和對照組2(iPTH600 pg/ml),療程3個月。分別于治療后1、2、3個月測定兩組血清全段iPTH、堿性磷酸酶(AKP)、血鈣、磷水平。3個月后,4組iPTH、AKP水平均較治療前有了顯著降低,差異有統(tǒng)計學意義(P0.05);與對照組1比較,治療組1的AKP水平、iPTH水平差異無統(tǒng)計學意義;與對照組2比較,治療組2的iPTH、AKP下降水平更為顯著(P0.05)。靜脈用骨化三醇能夠有效降低iPTH水平,與口服用骨化三醇相比較療效更為確切且較少引起高鈣血癥。
[Abstract]:To investigate the effect of different administration of ossifying triol on secondary hyperparathyroidism in patients with maintenance hemodialysis, 40 cases of hemodialysis complicated with secondary hyperthyroidism in blood purification center of hospital were selected. They were divided into intravenous ossifying triol combined hemodiafiltration group (treatment group) and oral ossifying triol combined hemodiafiltration group (control group). Treatment group 1 and control group 1: 300 pg/ml 鈮，

本文編號：1604698